Emerging biotech funding
Funding emerging biotech innovation from concept to clinical impact
Breakthrough science deserves a clear path to the clinic. For emerging biotech companies, securing the right funding and development expertise is essential to advancing novel therapies and delivering value to patients.
Demonstrating a viable and well-considered clinical development plan and Target Product Profile to potential investors is key to securing this funding. ICON can partner with biotech innovators to to assist with the optimisation of plans and pitch decks to support their discussions with investors, by applying deep expertise across trial design, regulatory strategy, and commercialisation.
Our relationships with leading venture funds, including those where ICON is a Limited Partner, have the potential to introduce our biotech customers to investors who understand the unique challenges of biotech development.
Whether you're preparing for your first IND or scaling toward pivotal trials, ICON provides the infrastructure, insight, and investor connectivity to move your science forward.
Optimising biotech funding whitepaper series
In this two-part whitepaper series on biotech funding, we firstly share insights on how biotechs can secure funding in a highly competitive market, and then shed light on the opportunities available to utilise these funds more effectively and efficiently.
